

410

```
03dec08 13:23:51 User208760 Session D3003.1
$0.80 0.220 DialUnits File1
$0.80 Estimated cost File1
$0.80 Estimated cost this search
$0.80 Estimated total session cost 0.220 DialUnits
```

File 410:Dialog Comm.-of-Interest Newsletters 2008 /Mar
(c) 2008 Dialog

```
Set Items Description
--- -----
```

```
? set hi ;set hi
HIGHLIGHT set on as ''
HIGHLIGHT set on as ''
? begin 5,73,155,399
03dec08 13:24:00 User208760 Session D3003.2
$0.00 0.117 DialUnits File410
$0.00 Estimated cost File410
$0.03 TELNET
$0.03 Estimated cost this search
$0.83 Estimated total session cost 0.337 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1926-2008/Nov W5

(c) 2008 The Thomson Corporation

File 73:EMBASE 1974-2008/Dec 02

(c) 2008 Elsevier B.V.

File 155:MEDLINE(R) 1950-2008/Nov 28

(c) format only 2008 Dialog

*File 155: NLM has suspended updating from 11/20-24/2008, as it begins preparations for the annual reload.

File 399:CA SEARCH(R) 1967-2008/UD=14922

(c) 2008 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

```
Set Items Description
--- -----
```

? e au=lawson alastair ?

```
Ref Items Index-term
E1 1 AU=LAWSON ALAN
E2 7 AU=LAWSON ALASTAIR
E3 0 *AU=LAWSON ALASTAIR ?
E4 1 AU=LAWSON ALASTAIR D
E5 12 AU=LAWSON ALASTAIR D G
E6 2 AU=LAWSON ALASTAIR DAVID GRIFFITHS
E7 5 AU=LAWSON ALEXANDER
E8 52 AU=LAWSON ALEXANDER M
E9 1 AU=LAWSON ALEXANDER M.
E10 1 AU=LAWSON ALEXANDER R
E11 1 AU=LAWSON ALEXIS A
E12 1 AU=LAWSON ALFRED J
```

Enter P or PAGE for more

? s e2-e6

```
7 AU=LAWSON ALASTAIR
0 AU=LAWSON ALASTAIR ?
1 AU=LAWSON ALASTAIR D
12 AU=LAWSON ALASTAIR D G
```

2 AU=LAWSON ALASTAIR DAVID GRIFFITHS
 S1 22 E2-E6
 ? e au=bourne timothy ?

Ref	Items	Index-term
E1	7	AU=BOURNE TIM
E2	3	AU=BOURNE TIMOTHY
E3	0	*AU=BOURNE TIMOTHY ?
E4	3	AU=BOURNE TIMOTHY F
E5	31	AU=BOURNE TOM
E6	1	AU=BOURNE TOM H
E7	6	AU=BOURNE V
E8	3	AU=BOURNE V L
E9	2	AU=BOURNE V T
E10	1	AU=BOURNE V.
E11	7	AU=BOURNE V.J.
E12	1	AU=BOURNE VICTOR

Enter P or PAGE for more

? s e1-e4

7	AU=BOURNE TIM
3	AU=BOURNE TIMOTHY
0	AU=BOURNE TIMOTHY ?
3	AU=BOURNE TIMOTHY F

S2 13 E1-E4

? s (s1 or s2) and (m(w)csf or csf(w)l)

Processing
 Processing

22	S1
13	S2
2241429	M
190121	CSF
9731	M(W)CSF
190121	CSF
13391559	1
5681	CSF(W)1
S3	3 (S1 OR S2) AND (M(W)CSF OR CSF(W)1)

? rd s3
 S4 2 RD S3 (unique items)

? t s4/3/all

4/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

18645295 BIOSIS NO.: 200510339795

Modulation of CSF-1-regulated post-natal development with anti-

CSF-1 antibody

AUTHOR: Wei Suwen; Lightwood Daniel; Ladyman Heather; Cross Sue; Neale

Helen; Griffiths Meryn; Adams Ralph; Marshall Diane; Lawson

Alastair; McKnight Andrew J; Stanley E Richard (Reprint)

AUTHOR ADDRESS: Albert Einstein Coll Med, Dept Dev and Mol Biol, 1300

Morris Pk Ave, Bronx, NY 10461 USA**USA

AUTHOR E-MAIL ADDRESS: rstanley@aecom.yu.edu

JOURNAL: Immunobiology 210 (2-4): p109-119 2005 2005

ISSN: 0171-2985

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/2 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

17655234 PMID: 17206685
Blockade of colony stimulating factor-1 (CSF-I) leads to inhibition of
DSS-induced colitis.
Marshall Diane; Cameron James; Lightwood Daniel; Lawson Alastair D
G
Celltech Centre of Excellence for Antibody Research, UCB, 216 Bath Road,
Slough SL1 4EN, UK. diane.marshall@celltech.ucb-group.com
Inflammatory bowel diseases (United States) Feb 2007, 13 (2) p219-24
, ISSN 1078-0998--Print Journal Code: 9508162
Publishing Model Print
Document type: In Vitro; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
? t s4/7/2

4/7/2 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

17655234 PMID: 17206685
Blockade of colony stimulating factor-1 (CSF-I) leads to inhibition of
DSS-induced colitis.
Marshall Diane; Cameron James; Lightwood Daniel; Lawson Alastair D
G
Celltech Centre of Excellence for Antibody Research, UCB, 216 Bath Road,
Slough SL1 4EN, UK. diane.marshall@celltech.ucb-group.com
Inflammatory bowel diseases (United States) Feb 2007, 13 (2) p219-24
, ISSN 1078-0998--Print Journal Code: 9508162
Publishing Model Print
Document type: In Vitro; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
BACKGROUND: Intestinal inflammation associated with inflammatory bowel
disease (IBD) is typically characterized by an inflammatory cell infiltrate
and pro-inflammatory cytokine production. Of particular interest, the
frequency of colony stimulating factor-1 (CSF-1)-expressing cells is
increased in active lesions. In this study, we have investigated the role
of CSF-1 in mucosal inflammation, using a murine model of
colitis induced by dextran sulfate sodium (DSS). METHODS: A neutralizing
anti-CSF-1 antibody was administered to Balb/c mice that
received DSS in their drinking water. Signs of colitis, such as clinical
disease score, cellular infiltrate, and cytokine production, were assessed.
RESULTS: Administration of a neutralizing anti-CSF-1 antibody
significantly inhibited DSS-induced colitis. Clinical symptoms, such as
weight loss and the appearance of diarrhea or fecal blood, were reduced by
CSF - ***1*** blockade; histologic scores were also improved. The
cellular infiltrate of macrophages and T cells was inhibited and a trend
toward reduced production of pro-inflammatory cytokines was noted.
CONCLUSIONS: This is the first study to demonstrate that CSF-1
plays an important role in mediating intestinal mucosal inflammation and
therefore may prove to be an attractive therapeutic target for intestinal
diseases such as inflammatory bowel disease.
Record Date Created: 20070502
Record Date Completed: 20070607
? s (m(w)csf or csf(w1)(20n)(antagon? or inhibit? or suppress? or block? or
prevent?) and (ibd or bowel or colitis or crohn?)

Processing
Processing
Processing

2241429 M
190121 CSF
9731 M(W)CSF
190121 CSF
13391559 1
5681 CSF(W)1
1405529 ANTAGON?
5398207 INHIBIT?
1138122 SUPPRESS?
1693610 BLOCK?
2985168 PREVENT?
3181 (M(W)CSF OR CSF(W)1) (20N) (((ANTAGON? OR INHIBIT?) OR
SUPPRESS?) OR BLOCK?) OR PREVENT?)
19140 IBD
213674 BOWEL
126633 COLITIS
91722 CROHN?
S5 15 (M(W)CSF OR CSF(W)1) (20N) (ANTAGON? OR INHIBIT? OR
SUPPRESS? OR BLOCK? OR PREVENT?) AND (IBD OR BOWEL OR
COLITIS OR CROHN?)

? rd s5

? s6 10 RD S5 (unique items)

? t s6/3/all

6/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

19158477 BIOSIS NO.: 200600503872
Intestinal microflora modulates mucosal expression of macrophage
colony-stimulating factor (M-CSF) and granulocyte-macrophage
colony-stimulating factor (GM-CSF)
AUTHOR: Takebayashi Koichi; Hokari Ryota; Okada Yoshikiyo; Okudaira Keisuke
; Kurihara Chic; Matsunaga Hisayuki; Mataka Norikazu; Komoto Syunsuke;
Watanabe Chikako; Kawaguchi Atsushir; Nagao Shigeaki; Itoh Kazuro; Tsuzuki
Yoshikazu; Miura Soichiro
JOURNAL: Gastroenterology 130 (4, Suppl. 2): pA368 APR 2006 2006
CONFERENCE/MEETING: Digestive Disease Week Meeting/107th Annual Meeting of
the American-Gastroenterological-Association Los Angeles, CA, USA May 19
-24, 2006; 20060519
SPONSOR: Amer Gastroenterol Assoc Inst
ISSN: 0016-5085
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

6/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18517824 BIOSIS NO.: 200510212324
Clinical significance of serum cytokine measurements in untreated
colorectal cancer patients: Soluble tumor necrosis factor receptor type I
- An independent prognostic factor
AUTHOR: Kaminska J (Reprint); Nowacki M P; Kowalska M; Rysinska A;
Chwalinski M; Fuksiewicz M; Michalski W; Chechlińska M
AUTHOR ADDRESS: Maria Skłodowska Curie Mem Canc Ctr, Dept Tumor Markers,

Roentgena 5, PL-02781 Warsaw, Poland**Poland
AUTHOR E-MAIL ADDRESS: kaminskaj@col.waw.pl
JOURNAL: Tumor Biology 26 (4): p186-194 2005 2005
ISSN: 1010-4283
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13616937 BIOSIS NO.: 199699250997
Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies
AUTHOR: Brattsand R (Reprint); Linden M
AUTHOR ADDRESS: Dep. Pharmacol., Astra Draco AB, PO Box 34, S-221 00 Lund, Sweden**Sweden
JOURNAL: Alimentary Pharmacology and Therapeutics 10 (SUPPL. 2): p81-90 1996 1996
ISSN: 0269-2813
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

6/3/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081822424 EMBASE No: 2007256512
Blockade of colony stimulating factor-1 (CSF-1) leads to inhibition of DSS-induced colitis
Marshall D.; Cameron J.; Lightwood D.; Lawson A.D.G.
Celltech Centre of Excellence for Antibody Research, UCB, 216 Bath Road, Slough SL1 4EN, United Kingdom
AUTHOR EMAIL: diane.marshall@celltech.ucb-group.com
CORRESP. AUTHOR/AFFIL: Marshall D.: Celltech Centre of Excellence for Antibody Research, UCB, 216 Bath Road, Slough SL1 4EN, United Kingdom
CORRESP. AUTHOR EMAIL: diane.marshall@celltech.ucb-group.com

Inflammatory Bowel Diseases (Inflammatory Bowel Dis.) (United States)
February 1, 2007, 13/2 (219-224)
CODEN: IBDBE ISSN: 1078-0998 eISSN: 1536-4844
DOI: 10.1002/ibd.20055
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 31

6/3/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0079834584 EMBASE No: 2004019350
Disrupted mucosal barrier in quiescent ulcerative colitis: Effect of metronidazole and of a symbiotic preparation in a pilot cross-over study
Marotta F.; Naito Y.; Tajiri H.; Lighthouse J.; Yoshioka M.; Ogliari C.; Bozzani A.; Fuji H.; Fesce E.
Gastroenterology Department, S. Giuseppe Hospital, via Pisanello 4, 20146

Milano, Italy
AUTHOR EMAIL: fmarchimede@libero.it
CORRESP. AUTHOR/AFFIL: Marotta F.: Gastroenterology Department, S.
Giuseppe Hospital, via Pisanello 4, 20146 Milano, Italy
CORRESP. AUTHOR EMAIL: fmarchimede@libero.it

Chinese Journal of Digestive Diseases (Chin. J. Dig. Dis.) (Australia)
December 1, 2003, 4/4 (180-185)
CODEN: CJDDA ISSN: 1443-9611
DOI: 10.1046/j.1443-9573.2003.t01-4-.x
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 41

6/3/6 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

14132627 PMID: 11408267
Neural change in Trichinella-infected mice is MHC II independent and
involves M-CSF-derived macrophages.
Galeazzi F; Lovato P; Blennerhassett P A; Haapala E M; Vallance B A;
Collins S M
Intestinal Diseases Research Program, Health Sciences Center, McMaster
University, Hamilton, Ontario, Canada L8N 3Z5.
American journal of physiology. Gastrointestinal and liver physiology (
United States) Jul 2001, 281 (1) pG151-8, ISSN 0193-1857--Print
Journal Code: 100901227
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

6/3/7 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

14075408 PMID: 11336164
Differential activation of cytokine secretion in primary human colonic
fibroblast/myofibroblast cultures.
Rogler G; Gelbmann C M; Vogl D; Brunner M; Scholmerich J; Falk W; Andus T
; Brand K
Dept. of Internal Medicine I, University of Regensburg, Germany.
grogler@ucsd.edu
Scandinavian journal of gastroenterology (Norway) Apr 2001, 36 (4)
p389-98, ISSN 0036-5521--Print Journal Code: 0060105
Publishing Model Print
Document type: Clinical Trial; Comparative Study; Controlled Clinical
Trial; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

6/3/8 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

144101028 CA: 144(7)101028n PATENT
Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
INVENTOR(AUTHOR): Chung, James, B.; Gabel, Christopher, A.; Jungbluth,
Gail, L.
LOCATION: USA
ASSIGNEE: Warner-Lambert Company LLC
PATENT: PCT International ; WO 200603517 A1 DATE: 20060112
APPLICATION: WO 2005IB2195 (20050616) *US 2004PV583943 (20040629)
PAGES: 91 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-031/53A; A61P-019/02B; A61P-017/06B; A61P-025/16B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR;
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG;
PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ;
UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW;
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/9 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

143006277 CA: 143(1)6277p PATENT
CSF-1 inhibitors for treatment and prophylaxis of inflammatory bowel
disease
INVENTOR(AUTHOR): Lawson, Alastair David Griffiths; Bourne, Timothy
LOCATION: UK
ASSIGNEE: Celltech R & D Limited
PATENT: PCT International ; WO 200546657 A2 DATE: 20050526
APPLICATION: WO 2004GB4652 (20041103) *GB 200325836 (20031105)
PAGES: 33 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-031/00A; A61K-039/395B; A61P-029/00B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

6/3/10 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

137346237 CA: 137(24)346237p PATENT
Methods for inhibiting macrophage colony-stimulating factor (M-CSF) and
c-fms-dependent cell signaling, and therapeutic use
INVENTOR(AUTHOR): Rajavashisth, Tripathi
LOCATION: USA
ASSIGNEE: Cedars-Sinai Medical Center
PATENT: PCT International ; WO 200287496 A2 DATE: 20021107

APPLICATION: WO 2002US12251 (20020417) *US PV287426 (20010430) *US 94365
(20020308)

PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH;
CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;
IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK;
MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR;
TT; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW;
AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR;
BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

? ds

Set	Items	Description
S1	22	E2-E6
S2	13	E1-E4
S3	3	(S1 OR S2) AND (M(W)CSF OR CSF(W)1)
S4	2	RD S3 (unique items)
S5	15	(M(W)CSF OR CSF(W)1) (20N) (ANTAGON? OR INHIBIT? OR SUPPRESS? OR BLOCK? OR PREVENT?) AND (IBD OR BOWEL OR COLITIS OR CROHN- ?)
S6	10	RD S5 (unique items)
		? s (m(w)csf or csf(w)1) and (treat? or therap? or inhibit? or suppress? or antagoni? or prevent? or block?) (20n) (ibd or bowel or colitis or crohn?)
		Processing
		Processing
		Processing
		Processing
		Processing
	2241429	M
	190121	CSF
	9731	M(W)CSF
	190121	CSF
	13391559	1
	5681	CSF(W)1
	9055617	TREAT?
	8472945	THERAP?
	5398207	INHIBIT?
	1138122	SUPPRESS?
	1405424	ANTAGONI?
	2985168	PREVENT?
	1693610	BLOCK?
	19140	IBD
	213674	BOWEL
	126633	COLITIS
	91722	CROHN?
	106411	(((((TREAT? OR THERAP?) OR INHIBIT?) OR SUPPRESS?) OR ANTAGONI?) OR PREVENT?) OR BLOCK?) (20N) (((IBD OR BOWEL) OR COLITIS) OR CROHN?)
S7	26	(M(W)CSF OR CSF(W)1) AND (TREAT? OR THERAP? OR INHIBIT? OR SUPPRESS? OR ANTAGONI? OR PREVENT? OR BLOCK?) (20N) (IBD OR BOWEL OR COLITIS OR CROHN?)
		? rd s7
	S8	18 RD S7 (unique items)
		? t s18/3/all
		>>>Set 18 does not exist
		? t s8/3/all

DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0020366865 BIOSIS NO.: 200800413804
Anti-inflammatory effects of opc-6535; PDE4 may be a new therapeutic
target in inflammatory bowel disease
AUTHOR: Ichikawa Hitoshi; Okamoto Susumu; Kamada Nobuhiko; Kobayashi Taku;
Takayama Tetsuro; Hisamatsu Tadakazu; Hibi Toshifumi
JOURNAL: Gastroenterology 134 (4, Suppl. 1): pA261-A262 APR 2008 2008
CONFERENCE/MEETING: Digestive Disease Week Meeting/109th Annual Meeting of
the American-Gastroenterological-Association San Diego, CA, USA May 17
-22, 2008; 20080517
SPONSOR: Amer Gastroenterol Assoc
ISSN: 0016-5085
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

8/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0020070010 BIOSIS NO.: 200800116949
Macrophages driven to a novel state of activation have anti-inflammatory
properties in mice
AUTHOR: Brem-Exner Beate G; Sattler Christine; Hutchinson James A; Koehl
Gudrun E; Kronenberg Katharina; Farkas Stefan; Inoue Seichiro; Blank
Christian; Knechtle Stuart J; Schlitt Hans J; Faendrich Fred; Geissler
Edward K (Reprint)
AUTHOR ADDRESS: Univ Regensburg, Dept Surg, Franz Josef Strauss Allee 11,
D-93053 Regensburg, Germany**Germany
AUTHOR E-MAIL ADDRESS: edward.geissler@klinik.uni-regensburg.de
JOURNAL: Journal of Immunology 180 (1): p335-349 JAN 1 2008 2008
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019953748 BIOSIS NO.: 200800000687
The protective effect of the vagus nerve in a murine model of chronic
relapsing colitis
AUTHOR: Ghia Jean-Eric; Blennerhassett Patricia; El-Sharkawy Rami T;
Collins Stephen M (Reprint)
AUTHOR ADDRESS: McMaster Univ, Med Ctr, Fac Hlth, 1200 Main St W, Hamilton,
ON L8N 3Z5, Canada**Canada
AUTHOR E-MAIL ADDRESS: scollins@mcmaster.ca
JOURNAL: American Journal of Physiology - Gastrointestinal and Liver
Physiology 293 (4): pG711-G718 OCT 2007 2007
ITEM IDENTIFIER: doi:10.1152/ajpgi.00240.2007
ISSN: 0193-1857
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/4 (Item 4 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019944559 BIOSIS NO.: 200700604300
The role of dendritic cells in the development of acute dextran sulfate sodium colitis
AUTHOR: Berndt Bradford E; Zhang Min; Chen Gwo-Hsiao; Huffnagle Gary; Lai Kevin; Zhang John; Kao John Y
JOURNAL: Gastroenterology 132 (4, Suppl. 2): pA390 APR 2007 2007
CONFERENCE/METING: Digestive Disease Week Meeting/108th Annual Meeting of the American-Gastroenterological-Association Washington, DC, USA May 19 -24, 2007; 20070519
SPONSOR: Amer Gastroenterol Assoc
Amer Assoc Study Liver Dis
Amer Soc Gastrointestinal Endoscopy
Soc Surg Alimentary Tract
ISSN: 0016-5085
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

8/3/5 (Item 5 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

19367509 BIOSIS NO.: 200700027250
The vagus nerve: A tonic inhibitory influence associated with inflammatory bowel disease in a murine model
AUTHOR: Ghia Jean Eric; Blennerhassett Patricia; Kumar-Ondiveeran Harry; Verdu Elena F; Collins Stephen M (Reprint)
AUTHOR ADDRESS: McMaster Univ, Med Ctr, Room 4W8, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada**Canada
AUTHOR E-MAIL ADDRESS: scollins@mcmaster.ca
JOURNAL: Gastroenterology 131 (4): p1122-1130 OCT 2006 2006
ISSN: 0016-5085
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/6 (Item 6 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

19158477 BIOSIS NO.: 200600503872
Intestinal microflora modulates mucosal expression of macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)
AUTHOR: Takebayashi Koichi; Hokari Ryota; Okada Yoshikiyo; Okudaira Keisuke; Kurihara Chic; Matsunaga Hisayuki; Mataka Norikazu; Komoto Syunsuke; Watanabe Chikako; Kawaguchi Atsushir; Nagao Shigeaki; Itoh Kazuro; Tsuzuki Yoshikazu; Miura Soichiro
JOURNAL: Gastroenterology 130 (4, Suppl. 2): pA368 APR 2006 2006
CONFERENCE/METING: Digestive Disease Week Meeting/107th Annual Meeting of the American-Gastroenterological-Association Los Angeles, CA, USA May 19 -24, 2006; 20060519
SPONSOR: Amer Gastroenterol Assoc Inst
ISSN: 0016-5085
DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract
LANGUAGE: English

8/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13616937 BIOSIS NO.: 199699250997
Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies
AUTHOR: Brattsand R (Reprint); Linden M
AUTHOR ADDRESS: Dep. Pharmacol., Astra Draco AB, PO Box 34, S-221 00 Lund, Sweden**Sweden
JOURNAL: Alimentary Pharmacology and Therapeutics 10 (SUPPL. 2): p81-90
1996 1996
ISSN: 0269-2813
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

8/3/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081822424 EMBASE No: 2007256512
Blockade of colony stimulating factor-1 (CSF-1) leads to inhibition of DSS-induced colitis
Marshall D.; Cameron J.; Lightwood D.; Lawson A.D.G.
Celltech Centre of Excellence for Antibody Research, UCB, 216 Bath Road, Slough SL1 4EN, United Kingdom
AUTHOR EMAIL: diane.marshall@celltech.ucb-group.com
CORRESP. AUTHOR/AFFIL: Marshall D.: Celltech Centre of Excellence for Antibody Research, UCB, 216 Bath Road, Slough SL1 4EN, United Kingdom
CORRESP. AUTHOR EMAIL: diane.marshall@celltech.ucb-group.com

Inflammatory Bowel Diseases (Inflammatory Bowel Dis.) (United States)
February 1, 2007, 13/2 (219-224)
CODEN: IBDNB ISSN: 1078-0998 eISSN: 1536-4844
DOI: 10.1002/ibd.20055
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 31

8/3/9 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080760873 EMBASE No: 2005405394
Implication for thiazolidinediones (TZDs) as novel potential anti-inflammatory drugs
Xu H.; Finas D.; Koster F.; Griesinger G.; Friedrich M.; Diedrich K.; Hornung D.
Department of Gynecology and Obstetrics, University of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
AUTHOR EMAIL: D.Hornung@gmx.de
CORRESP. AUTHOR/AFFIL: Hornung D.: Department of Gynecology and Obstetrics, University of Schleswig-Holstein, Campus Luebeck, Luebeck,

Germany

CORRESP. AUTHOR EMAIL: D.Hornung@gmx.de

Current Medicinal Chemistry: Anti-Inflammatory and Anti-Allergy Agents (Curr. Med. Chem.: Anti-Inflammatory Anti-Allergy Agents) (Netherlands)
October 1, 2005, 4/5 (531-541)
CODEN: CMCAG ISSN: 1568-0142
DOI: 10.2174/156801405774330367
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 121

8/3/10 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0079834584 EMBASE No: 2004019350

Disrupted mucosal barrier in quiescent ulcerative colitis: Effect of metronidazole and of a symbiotic preparation in a pilot cross-over study
Marotta F.; Naito Y.; Tajiri H.; Lighthouse J.; Yoshioka M.; Ogliari C.; Bozzani A.; Fuji H.; Fesce E.
Gastroenterology Department, S. Giuseppe Hospital, via Pisanello 4, 20146 Milano, Italy
AUTHOR EMAIL: fmarchimede@libero.it
CORRESP. AUTHOR/AFFIL: Marotta F.: Gastroenterology Department, S. Giuseppe Hospital, via Pisanello 4, 20146 Milano, Italy
CORRESP. AUTHOR EMAIL: fmarchimede@libero.it

Chinese Journal of Digestive Diseases (Chin. J. Dig. Dis.) (Australia)
December 1, 2003, 4/4 (180-185)
CODEN: CJDDA ISSN: 1443-9611
DOI: 10.1046/j.1443-9573.2003.t01-4-.x
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 41

8/3/11 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0078849047 EMBASE No: 2002012675

Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine
Klebl F.H.; Olsen J.E.; Jain S.; Doe W.F.
Klinik/Poliklinik fuer Innere Med. I, Klinikum der Universitaet Regensburg, 93042 Regensburg, Germany
CORRESP. AUTHOR/AFFIL: Klebl F.H.: Klinik/Poliklinik fuer Innere Med. I, Klinikum der Universitaet Regensburg, 93042 Regensburg, Germany
CORRESP. AUTHOR EMAIL: frank.klebl@klinik.uni-regensburg.de

Journal of Pathology (J. Pathol.) (United Kingdom) December 1, 2001, 195/5 (609-615)
CODEN: JPTLA ISSN: 0022-3417
DOI: 10.1002/path.991
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 34

8/3/12 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078691793 EMBASE No: 2001298123
Altered response of intestinal mucosal fibroblasts to profibrogenic
cytokines in inflammatory bowel disease
Lawrance I.C.; Maxwell L.; Doe W.
Division of Gastroenterology, Fremantle Hospital, Alma St., Fremantle, WA
6959, Australia
CORRESP. AUTHOR/AFFIL: Lawrance I.C.: Division of Gastroenterology,
Fremantle Hospital, Alma St., Fremantle, WA 6959, Australia
CORRESP. AUTHOR EMAIL: ian.c.lawrance@health.wa.gov.au

Inflammatory Bowel Diseases (Inflammatory Bowel Dis.) (United States)
September 4, 2001, 7/3 (226-236)
CODEN: IBDNB ISSN: 1078-0998
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 52

8/3/13 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

148239200 CA: 148(11)239200b PATENT
Preparation of N-oxide imidazoacridinones for treating diseases
INVENTOR(AUTHOR): Ajami, Alfred M.
LOCATION: USA
ASSIGNEE: Xanthus Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200816700 A2 DATE: 20080207
APPLICATION: WO 2007US17300 (20070802) *US 2006PV835063 (20060802)
PAGES: 68pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

C07D-0471/06	A	I	F	B	20060101	H	EP
A61K-0031/435	A	I	L	B	20060101	H	EP
A61P-0035/00	A	I	L	B	20060101	H	EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI;
GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP;
KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY;
MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK;
SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/14 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

148215080 CA: 148(10)215080m PATENT
Morpholino imidazoacridinone compounds for treating inflammatory and
demyelinating diseases and cancers
INVENTOR(AUTHOR): Ajami, Alfred M.
LOCATION: USA
ASSIGNEE: Xanthus Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200816661 A2 DATE: 20080207
APPLICATION: WO 2007/0517224 (20070802) *US 2006PV835064 (20060802)
PAGES: 59pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

IPCR/8	Level	Value	Position	Status	Version	Action	Source	Office:
C07D	0471	06	A	I	F	B	20060101	H EP
A61K	0031	437	A	I	L	B	20060101	H EP
A61P	0035	00	A	I	L	B	20060101	H EP
A61P	0029	00	A	I	L	B	20060101	H EP
A61P	0025	00	A	I	L	B	20060101	H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/15 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

144101028 CA: 144(7)101028n PATENT

Combination therapies utilizing benzamide inhibitors of the p2x7 receptor

INVENTOR(AUTHOR): Chung, James, B.; Gabel, Christopher, A.; Jungbluth, Gail, L.

LOCATION: USA

ASSIGNEE: Warner-Lambert Company LLC

PATENT: PCT International ; WO 200603517 A1 DATE: 20060112

APPLICATION: WO 20051B2195 (20050616) *US 2004PV583943 (20040629)

PAGES: 91 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-031/53A; A61P-019/02B; A61P-017/06B; A61P-025/16B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/16 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

143006277 CA: 143(1)6277p PATENT

CSF-1 inhibitors for treatment and prophylaxis of inflammatory bowel disease

INVENTOR(AUTHOR): Lawson, Alastair David Griffiths; Bourne, Timothy

LOCATION: UK

ASSIGNEE: Celltech R & D Limited

PATENT: PCT International ; WO 200546657 A2 DATE: 20050526

APPLICATION: WO 2004GB4652 (20041103) *GB 200325836 (20031105)

PAGES: 33 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-031/00A; A61K-039/395B; A61P-029/00B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/17 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142315225 CA: 142(17)315225g PATENT

Human anti-M-CSF antibodies for diagnosis and treatment of inflammation, neurological disease, atherogenesis, cardiac disease and cancer

INVENTOR(AUTHOR): Bedian, Vahe; Devalaraja, Madhav Narasimha; Low, Joseph Edwin; Mobley, James Leslie; Kellermann, Sirid-Aimee; Foltz, Ian; Haak-Frendscho, Mary

LOCATION: USA

ASSIGNEE: Warner-Lambert Company LLC; Abgenix, Inc.

PATENT: Britain UK Pat. Appl. ; GB 2405873 A1 DATE: 20050316

APPLICATION: GB 200420044 (20040909) *US 2003PV502163 (20030910)

PAGES: 155 pp. CODEN: BAXXDU LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C07K-016/24A; A61K-039/395B; A61P-029/00B; A61P-035/00B

8/3/18 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

137346237 CA: 137(24)346237p PATENT

Methods for inhibiting macrophage colony-stimulating factor (M-CSF) and c-fms-dependent cell signaling, and therapeutic use

INVENTOR(AUTHOR): Rajavashisth, Tripathi

LOCATION: USA

ASSIGNEE: Cedars-Sinai Medical Center

PATENT: PCT International ; WO 200287496 A2 DATE: 20021107

APPLICATION: WO 2002US12251 (20020417) *US PV287426 (20010430) *US 94365 (20020308)

PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; UA; UG; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

? t s8/7/6,7,11,12

8/7/6 (Item 6 from file: 5)

19158477 BIOSIS NO.: 200600503872

Intestinal microflora modulates mucosal expression of macrophage
colony-stimulating factor (M-CSF) and granulocyte-macrophage
colony-stimulating factor (GM-CSF)

AUTHOR: Takebayashi Koichi; Hokari Ryota; Okada Yoshikiyo; Okudaira Keisuke
; Kurihara Chic; Matsunaga Hisayuki; Matakai Norikazu; Komoto Syunsuke;
Watanabe Chikako; Kawaguchi Atsushir; Nagao Shigeaki; Itoh Kazuro; Tszuki
Yoshikazu; Miura Soichiro

JOURNAL: Gastroenterology 130 (4, Suppl. 2): pA368 APR 2006 2006

CONFERENCE/MEETING: Digestive Disease Week Meeting/107th Annual Meeting of
the American-Gastroenterological-Association Los Angeles, CA, USA May 19
-24, 2006; 20060519

SPONSOR: Amer Gastroenterol Assoc Inst

ISSN: 0016-5085

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: BACKGROUND & AIMS: Enterobacteria have been implicated in the pathogenesis of inflammatory bowel diseases (IBD), and reported to be essential for the initiation of experimental murine ***colitis***. Mucosal macrophages (mM Phi) are also related to the pathogenesis of IBD by secreting both inflammatory and inhibitory cytokines in response to enterobacteria. Because mM Phi differentiates into two different phenotypes under macrophage colony-stimulating factor (M-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), we speculate enterobacteria may modulate intestinal inflammation through different CSF induction in the intestinal mucosa. However, there is no report how changes of bacterial flora affects CSF expression in vivo. In this study, we compared CSF expression in the intestine under germ free (GF) or specific pathogen free (SPF) condition. We also examined effects of specific enterobacterial colonization on CSF expression in GF mice. MATERIALS & METHODS: We used male IQ1 mice bred under GF or SPF conditions. Jejunal, ileal and colonic mucosa were removed. Messenger RNA of M-CSF, GM-CSF, M-CSF receptor, GM-CSF receptor and TNF-alpha were measured by quantitative RT-PCR. The expression of adhesion molecules in the ileal mucosa were evaluated by immunohistochemistry. In some GF mice, Bifidobacterium bifidum or Bacteroides vulgatus was inoculated and changes of CSF expression were evaluated after 21 days. RESULTS: In colonic mucosa, GM-CSF expression significantly decreased and GM-CSF receptor expression decreased slightly in GF mice compared with SPF mice. Interestingly, on the other hand ***M*** - ***CSF*** expression increased slightly in GF mice. TNF-alpha expression was significantly suppressed in GF mice, comparable with the deviation to ***M*** - ***CSF*** dominant environment in GF condition. Immunohistochemical study revealed the significant increase in infiltration of CD4+ and beta 7-integrin+ cells and expression of MadCAM1+ vessels in SPF mice than GF mice. Even after inoculation of enterobacteria in GF mice, however, there was no sign of inflammation and both bacteria significantly decreased GMCSF receptor expression, while M-CSF receptor expression increased slightly, maintaining the enhanced M-CSF dominance. In the jejunal or ileal mucosa, effects of enterobacteria to the M-CSF deviation was less dominant than in the colonic mucosa. CONCLUSIONS: Results suggest that intestinal microflora regulates cytokine production and adhesion molecule expression via modulation of ***M*** - ***CSF*** and GM-CSF expression. The M-CSF dominant environment in GF mice may be related to the decreased inflammatory cytokine response, thus giving us a suggestion of

CSF as one of ***therapeutic*** targets for ***IBD*** .

8/7/77 (Item 7 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13616937 BIOSIS NO.: 199699250997

Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies

AUTHOR: Brattsand R (Reprint); Linden M

AUTHOR ADDRESS: Dep. Pharmacol., Astra Draco AB, PO Box 34, S-221 00 Lund, Sweden**Sweden

JOURNAL: Alimentary Pharmacology and Therapeutics 10 (SUPPL. 2): p81-90
1996 1996

ISSN: 0269-2813

DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Glucocorticoids inhibit the expression and action of most cytokines. This is part of the in vivo feed-back system between inflammation-derived cytokines and CNS-adrenal produced corticosteroids with the probable physiological relevance to balance parts of the host defence and anti-inflammatory systems of the body. Glucocorticoids modulate cytokine expression by a combination of genomic mechanisms. The activated glucocorticoid-receptor complex can (i) bind to and inactivate key proinflammatory transcription factors (e.g. AP-1, NF-kappa-B). This takes place at the promoter responsive elements of these factors, but has also been reported without the presence of DNA; (ii) via glucocorticoid responsive elements (GRE), upregulate the expression of cytokine inhibitory proteins, e.g. I-kappa-B, which inactivates the transcription factor NF-kappa-B and thereby the secondary expression of a series of cytokines, (iii) reduce the half-life time and utility of cytokine mRNAs. In studies with triggered human blood mononuclear cells in culture, glucocorticoids strongly diminish the production of the 'initial phase' cytokines IL-1-beta and TNF-alpha and the 'immunomodulatory' cytokines IL-2, IL-3, IL-4, IL-5, IL-10, IL-12 and IFN-gamma, as well as of IL-6, IL-8 and the growth factor GM-CSF. While steroid treatment broadly attenuates cytokine production, it cannot modulate it selectively, e.g. just the TH-0, the TH-1 or the TH-2 pathways. The production of the 'anti-inflammatory' IL-10 is also inhibited. The exceptions of steroid down-regulatory activity on cytokine expression seem to affect 'repair phase' cytokines like TGF-beta and PDGF. These are even reported to be upregulated, which may explain the rather weak steroid dampening action on healing and fibrotic processes. Some growth factors, e.g. G-CSF and ***M*** - ***CSF***, are only weakly affected. In addition to diminishing the production of a cytokine, steroids can also often inhibit its subsequent actions. Because cytokines work in cascades, this means that steroid treatment can block expression of the subsequent cytokines. The blocked cytokine activity does not depend on a reduced cytokine receptor expression; in fact available in vitro investigations show that while the cytokine expression is blunted, its receptor is upregulated. The cellular studies presented here may represent the maximum potential of steroids to modulate cytokine expression in human mononuclear cells. It remains to be determined by clinical-experimental studies how effective cytokine modulation can be achieved in situ in inflamed bowel by systemic or by topical steroid ***therapy***. Such studies may also answer whether a blocked cytokine production/action is the key or just a secondary mechanism behind the unique efficacy of steroids in active inflammatory ***bowel*** disease.

8/7/11 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078849047 EMBASE No: 2002012675
Expression of macrophage-colony stimulating factor in normal and
inflammatory bowel disease intestine
Klebl F.H.; Olsen J.E.; Jain S.; Doe W.F.
Klinik/Poliklinik fuer Innere Med. I, Klinikum der Universitaet
Regensburg, 93042 Regensburg, Germany
CORRESP. AUTHOR/AFFIL: Klebl F.H.: Klinik/Poliklinik fuer Innere Med. I,
Klinikum der Universitaet Regensburg, 93042 Regensburg, Germany
CORRESP. AUTHOR EMAIL: frank.klebl@klinik.uni-regensburg.de

Journal of Pathology (J. Pathol.) (United Kingdom) December 1, 2001,
195/5 (609-615)
CODEN: JPTLA ISSN: 0022-3417
DOI: 10.1002/path.991
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 34

Mucosal macrophages have been implicated in the pathogenesis of
inflammatory bowel disease (IBD). Macrophage-colony stimulating factor (M-CSF)
influences monocyte/macrophage proliferation, differentiation, and activation. Serum levels are increased in active IBD,
but little is known about its role in mucosal inflammation. This study was
undertaken to determine the distribution, frequency, and level of M-
CSF expression in normal and IBD-affected intestine. RNA and tissue
were studied from patients with Crohn's disease (CD) and ulcerative colitis
(UC) as well as from histologically normal colon. Tissue from intestinal
tuberculosis and ischaemic colitis patients served as controls. ***M*** -
CSF mRNA and protein were examined by semi-quantitative reverse
transcriptase-polymerase chain reaction (RT-PCR), in situ hybridisation,
and immunohistochemistry, respectively. ***M*** - ***CSF*** mRNA and protein
were detected in histologically normal intestine, but their expression was
largely confined to the mucosa. In active IBD, the frequency of ***M*** -
CSF-expressing cells was significantly increased and their
distribution markedly altered, although no increase in mucosal M-
CSF mRNA levels in intestinal tissue was observed. The changes were
not specific to IBD, as there were similar findings in intestinal
tuberculosis and ischaemic colitis. The marked alteration observed in
M-CSF expression in IBD and the importance of this cytokine in
stimulating macrophage functions suggest that M-CSF may
contribute to the pathogenesis of the IBD lesion. Copyright (c) 2001 John
Wiley & Sons, Ltd.

8/7/12 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078691793 EMBASE No: 2001298123
Altered response of intestinal mucosal fibroblasts to profibrogenic
cytokines in inflammatory bowel disease
Lawrance I.C.; Maxwell L.; Doe W.
Division of Gastroenterology, Fremantle Hospital, Alma St., Fremantle, WA
6959, Australia
CORRESP. AUTHOR/AFFIL: Lawrance I.C.: Division of Gastroenterology,

Fremantle Hospital, Alma St., Fremantle, WA 6959, Australia
CORRESP. AUTHOR EMAIL: ian.c.lawrance@health.wa.gov.au

Inflammatory Bowel Diseases (Inflammatory Bowel Dis.) (United States)
September 4, 2001, 7/3 (226-236)
CODEN: IBDNB ISSN: 1078-0998
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 52

Background and Aims: Fibrosis is a major complication of inflammatory bowel disease (IBD), which may be mediated by the intestinal fibroblast. Our aim was to isolate and characterize mucosal fibroblasts from histologically normal intestine (control), ulcerative colitis (UC), inflamed Crohn's disease (CD), and fibrosed CD intestine. Methods: Fibroblasts were characterized by light and electron microscopy and immunohistochemistry. Fibroblast collagen secretion and proliferation were determined by SUP 3H-proline and SUP 3H-thymidine incorporation, and the effects of exposure to interleukin (IL)-1beta, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF)-beta1, insulin-like growth factor (IGF)-1, and macrophage colony stimulating factor (***M*** - ***CSF***) were determined. Results: No difference in doubling time was observed between the fibroblast populations from UC and CD intestine. All proliferated faster than fibroblasts from control intestine. Collagen secretion from IBD fibroblasts, independent of type, was increased compared with control fibroblasts and PDGF, bFGF, and TGF-beta1-induced collagen secretion from IBD fibroblasts. Conclusions: These results suggest the presence of an activated subpopulation of fibroblasts in both UC and CD tissue irrespective of the presence of tissue fibrosis or disease type.

?